Several down, a few to go: Histamine H3 receptor ligands making the final push towards the market?

Expert Opinion on Investigational Drugs

Volumn 20, Issue 12, 2011, Pages 1629-1648

  Kuhne, Sebastiaan ^a   Wijtmans, Maikel ^a   Lim, Herman D ^a   Leurs, Rob ^a   De Esch, Iwan J P ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

ADHD; Allergic rhinitis; Alzheimer's disease; Antagonists; Clinical trials; Cognition; Excessive daytime sleepiness; Heteroreceptor; Histamine H3 receptor; Inverse agonists; Narcolepsy; Schizophrenia

Indexed keywords

6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; ABT 288; APD 916; AZD 5213; AZELASTINE; BAVISANT; BF 2649; CEP 26401; FUB 181; GSK 1004723; GSK 239512; GSK 835726; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; HPP 404; IRDABISANT; JNJ 31001074; JNJ 39220675; MK 0249; PF 0354746; PF 03654746; PITOLISANT; S 38093; SAR 110894; SCH 497079; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; DAYTIME SOMNOLENCE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; NARCOLEPSY; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; REVIEW; SCHIZOPHRENIA; SLEEP APNEA SYNDROME; STRUCTURE ACTIVITY RELATION;

EID: 81555208935     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.625010     Document Type: Review

References (147)

1. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003;20(2):121-30 (Pubitemid 37271382)
2. Leurs R, Chazot PL, Shenton FC, et al. Molecular and biochemical pharmacology of the histamine H4 receptor. Br J Pharmacol 2009;157(1):14-23
3. de Esch IJ, Thurmond RL, Jongejan A, Leurs R. The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 2005;26(9):462-9 (Pubitemid 41207878)
4. Celanire S, Wijtmans M, Talaga P, et al. Keynote review: histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today 2005;10(23-24):1613-27 (Pubitemid 41817610)
5. Leurs R, Bakker RA, Timmerman H, de Esch IJ. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 2005;4(2):107-20 . Review on the H3R. (Pubitemid 40277492)
6. Parsons ME, Ganellin CR. Histamine and its receptors. Br J Pharmacol 2006;147(Suppl 1):S127-35 (Pubitemid 43077270)
7. Hough LB. Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 2001;59(3):415-19 (Pubitemid 32179917)
8. Shimamura T, Shiroishi M, Weyand S, et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 2011;475(7354):65-70
9. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983;302(5911):832-7 (Pubitemid 13125123)
10. Arrang JM, Garbarg M, Lancelot JC, et al. Highly potent and selective ligands for histamine H3-receptors. Nature 1987;327(6118):117-23 . First report on selective H3R ligands.
11. Schlicker E, Kathmann M. Modulation of in vitro neurotransmission in the CNS and in the retina via H3 heteroreceptors. In: Leurs R, Timmerman H, editors. The histamine H3 receptor; a target for new drugs. Elsevier; Amsterdam, The Netherlands: 1998. p. 13-16
12. Martinez-Mir MI, Pollard H, Moreau J, et al. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res 1990;526(2):322-7 (Pubitemid 20307895)
13. Bertraccini G. Functional role of the histamine H3 receptor in peripheral tissues. In: Leurs R, Timmerman H, editors. The histamine H3 receptor; a target for new drugs. Elsevier; Amsterdam, The Netherlands: 1998. 59-111
14. Wijtmans M, Leurs R, de Esch I. Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin Investig Drugs 2007;16(7):967-85 . Review on the therapeutic areas involving the H3R. (Pubitemid 47074155)
15. Passani MB, Blandina P. Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci 2011;32(4):242-9
16. Leurs R, Vischer HF, Wijtmans M, de Esch IJ. En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family. Trends Pharmacol Sci 2011;32(4):250-7
17. Lovenberg TW, Roland BL, Wilson SJ, et al. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999;55(6):1101-7 (Pubitemid 29252378)
18. Smits RA, Leurs R, de Esch IJ. Major advances in the development of histamine H4 receptor ligands. Drug Discov Today 2009;14(15-16):745-53
19. Bongers G, Bakker RA, Leurs R. Molecular aspects of the histamine H3 receptor. Biochem Pharmacol 2007;73(8):1195-204
20. Lovenberg TW, Pyati J, Chang H, et al. Cloning of rat histamine H3 receptor reveals distinct species pharmacological profiles. J Pharmacol Exp Ther 2000;293(3):771-8 (Pubitemid 30417841)
21. Chen J, Liu C, Lovenberg TW. Molecular and pharmacological characterization of the mouse histamine H3 receptor. Eur J Pharmacol 2003;467(1-3):57-65 (Pubitemid 36423385)
22. Cassar S. Cloning of the guinea pig H3 receptor. Neuroreport 2000;11(12):L3-4
23. Tardivel-Lacombe J, Rouleau A, Heron A, et al. Cloning and cerebral expression of the guinea pig histamine H3 receptor: evidence for two isoforms. Neuroreport 2000;11(4):755-9 (Pubitemid 30173918)
24. Peitsaro N, Sundvik M, Anichtchik OV, et al. Identification of zebrafish histamine H1, H2 and H3 receptors and effects of histaminergic ligands on behavior. Biochem Pharmacol 2007;73(8):1205-14 (Pubitemid 46413182)
25. Yao BB, Sharma R, Cassar S, et al. Cloning and pharmacological characterization of the monkey histamine H3 receptor. Eur J Pharmacol 2003;482(1-3):49-60 (Pubitemid 37505926)
26. Strakhova MI, Fox GB, Carr TL, et al. Cloning and characterization of the monkey histamine H3 receptor isoforms. Eur J Pharmacol 2008;601(1-3):8-15
27. Hancock AA, Esbenshade TA, Krueger KM, Yao BB. Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci 2003;73(24):3043-72 (Pubitemid 37205140)
28. Ireland-Denny L, Parihar AS, Miller TR, et al. Species-related pharmacological heterogeneity of histamine H3 receptors. Eur J Pharmacol 2001;433(2-3):141-50 (Pubitemid 34045172)
29. Available from: www.ensembl.org [Last accessed 24 August 2011]
30. Bongers G, Krueger KM, Miller TR, et al. An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activity. J Pharmacol Exp Ther 2007;323(3):888-98 (Pubitemid 350146058)
31. Wieland K, Bongers G, Yamamoto Y, et al. Constitutive activity of histamine H3 receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H3 antagonists. J Pharmacol Exp Ther 2001;299(3):908-14 (Pubitemid 33104958)
32. Morisset S, Rouleau A, Ligneau X, et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 2000;408(6814):860-4 (Pubitemid 32016096)
33. Berlin M, Boyce CW, de Lera Ruiz M. Histamine H3 receptor as a drug discovery target. J Med Chem 2011;54(1):25-53
34. Brioni JD, Esbenshade TA, Garrison TR, et al. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther 2011;336(1):38-46
35. Gemkow MJ, Davenport AJ, Harich S, et al. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today 2009;14(9-10):509-15
36. Yang R, Hey JA, Aslanian R, Rizzo CA. Coordination of histamine H3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology 2002;66(3):128-35 (Pubitemid 35316924)
37. Lazewska D, Kiec-Kononowicz K. Recent advances in histamine H3 receptor antagonists/inverse agonists. Expert Opin Ther Patent 2011;20(9):1147-69
38. Stark H. Histamine receptors. Biotrend. Review. No.1 11-2007
39. Schwartz J. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 2011;163(4):713-21
40. Ganellin CR, Leurquin F, Piripitsi A, et al. Synthesis of potent non-imidazole histamine H3-receptor antagonists. Arch Pharm (Weinheim) 1998;331(12):395-404 (Pubitemid 29035302)
41. Linney ID, Buck IM, Harper EA, et al. Design, synthesis, and structure-activity relationships of novel non-imidazole histamine H3 receptor antagonists. J Med Chem 2000;43(12):2362-70 (Pubitemid 30431934)
42. Meier G, Apelt J, Reichert U, et al. Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists. Eur J Pharm Sci 2001;13(3):249-59 (Pubitemid 32522577)
43. Ligneau X, Perrin D, Landais L, et al. BF2.649 [1-{3-[3-(4-Chlorophenyl) propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther 2007;320(1):365-75 (Pubitemid 46025751)
44. Ligneau X, Landais L, Perrin D, et al. Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol 2007;73(8):1215-24 (Pubitemid 46420689)
45. Burban A, Sadakhom C, Dumoulin D, et al. Modulation of prepulse inhibition and stereotypes in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor inverse agonists. Psychopharmacology (Berl) 2010;210(4):591-604
46. Available from: http://clinicaltrials.gov; Identifier: NCT00690274 Study to demonstrate cognitive enhancing effects of BF2.649. [Last accessed 15 June 2011]
47. Sander K, Kottke T, Stark H. Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull 2008;31(12):2163-81
48. Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: studies in orexin-/-mice and patients. Neurobiol Dis 2008;30(1):74-83
49. Anrhulf I. Results of clinical trials of tripolisant in narcolepsy and Parkinson's disease. Eur Neurophychopharmacol 2009;19:S204
50. Available from: http://clinicaltrials.gov; Identifier: NCT01072968 BF2.649 in patients with obstructive sleep apnea (OSA), still complaining of excessive daytime sleepiness (EDS) and refusing to be treated by continuous positive airway pressure (CPAP) (HAROSAII). [Last accessed 15 June 2011]
51. Available from: http://clinicaltrials.gov; Identifier: NCT01036139 Efficacy and safety of BF2.649 in excessive daytime sleepiness (EDS) in Parkinson's disease (HARPS 1). [Last accessed 15 June 2011]
52. Available from: http://clinicaltrials.gov; Identifier: NCT01066442 Efficacy and safety of BF2.649 in excessive daytime sleepiness (EDS) in Parkinson's disease (HARPS 2) (HARPS2). [Last accessed 15 June 2011]
53. Available from: http://clinicaltrials.gov; Identifier: NCT01067222 Efficacy and safety study of BF2.649 in the treatment of excessive daytime sleepiness in narcolepsy (harmony1). [Last accessed 15 June 2011]
54. Available from: http://clinicaltrials.gov; Identifier: NCT01067235 Efficacy and safety study of BF2.649 and BF2.649 add on Modafinil on cataplexy in patients with narcolespy (harmony II). [Last accessed 15 June 2011]
55. Nagase T, Mizutani T, Ishikawa S, et al. Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists. J Med Chem 2008;51(15):4780-9
56. Zoethout RW, Iannone R, Bloem BR, et al. The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol. J Psychopharmacol 2011;published online 18 February 2011; doi: 101177/0269881111398685 2011 Feb 24
57. Iannone R, Palcza J, Renger JJ, et al. Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers. Clin Pharmacol Ther 2010;88(6):831-9
58. Available from: http://clinicaltrials.gov; Identifier: NCT00420420 MK0249 for the symptomatic treatment of Alzheimer's disease (MK0249-011) (completed). [Last accessed 15 June 2011]
59. Available from: http://clinicaltrials.gov; Identifier: NCT00475735 A study to test the safety and efficacy of MK0249 in patients with ADHD (0249-018) (completed). [Last accessed 15 June 2011]
60. Available from: http://clinicaltrials.gov; Identifier: NCT00506077 MK0249 for the treatment of cognitive impairment in patients with schizophrenia (0249-016). [Last accessed 15 June 2011]
61. Egan M, Harper L, Gottwald R, et al. Effects of H3 inverse agonist MK-0249 on cognitive performance in patients with schizophrenia. In ACNP 48th Annual Meeting; 6-10 December 2009; Hollywood, FL. American College of Neurophsychophramacology; Nashville, TN
62. James LM, Iannone R, Palcza J, et al. Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers. Psychopharmacology (Berl) 2011;215(4):643-53
63. Le S, Gruner JA, Mathiasen JR, et al. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. J Pharmacol Exp Ther 2008;325(3):902-9 (Pubitemid 351724342)
64. Available from: http://clinicaltrials.gov; Identifier: NCT00620659 Treatment of refractory excessive daytime sleepiness in patients with obstructive sleep apnea/hypopnea syndrome (OSA/HS) using nasal continuous positive airway pressure (nCPAP) therapy (0249-015). [Last accessed 15 June 2011]
65. Available from: http://www.merck.com/research/pipeline/Merck%20October% 202009%20Combined%20Pipeline.pdf [Last accessed 22 May 2011]
66. Medhurst AD, Atkins AR, Beresford IJ, et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007;321(3):1032-45 (Pubitemid 46762709)
67. Armer R, Warne P,Witherington J. Highlights of the Society for Medicines Research Symposium held December 8, 2005, in London, United Kingdom. Discovery of a novel series of potent, orally active histamine H3 receptor antagonists. Drug News Perspect 2006;19(1):67-9
68. Ashworth S, Rabiner EA, Gunn RN, et al. Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. J Nucl Med 2010;51(7):1021-9
69. Giannoni P, Medhurst AD, Passani MB, et al. Regional differential effects of the novel histamine H3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5- tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-p yridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. J Pharmacol Exp Ther 2010;332(1):164-72
70. Available from: http://www.gsk.com/investors/reps05/annual-report-2005. pdf [Last accessed 22 May 2011]
71. Medhurst SJ, Collins SD, Billinton A, et al. Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain. Pain 2008;138(1):61-9
72. Hsieh GC, Honore P, Pai M, et al. Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems. Brain Res 2010;1354:74-84
73. Available from: http://clinicaltrials.gov; Identifier: NCT00387413 A study of GSK189254 and duloxetine in the electrical hyperalgesia model of healthy volunteers. [Last accessed 15 June 2011]
74. Guo RX, Anaclet C, Roberts JC, et al. Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/-mice. Br J Pharmacol 2009;157(1):104-17
75. Available from: http://clinicaltrials.gov; Identifier: NCT00366080 Effectiveness of the drug GSK189254 in treating patients with narcolepsy. [Last accessed 15 June 2011]
76. Available from: www.gsk.com/investors/reps08/GSK-Report-2008-full.pdf [Last accessed 22 May 2011]
77. Letavic MA, Aluisio L, Atack JR, et al. Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical development. Bioorg Med Chem Lett 2010;20(14):4210-14
78. Galici R, Rezvani AH, Aluisio L, et al. JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl) 2011;214(4):829-41
79. Pippel DJ, Mills JE, Pandit CR, et al. First, second and third generation scalable syntheses of two potent H3 antagonists. Org Process Res Dev 2011;15(3):638-48
80. Available from: http://clinicaltrials.gov; Identifier: NCT00804687 Safety and efficacy of JNJ-39220675 in participants with allergic rhinitis. [Last accessed 15 June 2011]
81. Varty LM, Gustafson E, Laverty M, Hey JA. Activation of histamine H3 receptors in human nasal mucosa inhibits sympathetic vasoconstriction. Eur J Pharmacol 2004;484(1):83-9 (Pubitemid 38068537)
82. Carruthers NI. Translational approaches towards the identification of a histamine H3 receptor antagonist and its' clinical evaluation for the symptomatic treatment of allergic rhinitis. Abstracts of the 39th Annual Meeting of the European Histamine Research Society; 13-16 July 2010; Durham, United Kingdom. Inflamm Res 2010; 59(Suppl 4):S339
83. Panula P, Nuutinen S. Histamine and H3 receptor in alcohol-related behaviors. J Pharmacol Exp Ther 2011;336(1):9-16
84. Schmidt AW, Butler T, Chandrasekaran R, et al. PF-03654746: A potent and selective histamine H3 receptor antagonist. 734.5/L23 2009 Neuroscience Meeting Planner; Society for Neuroscience; Chicago, IL; 2009
85. Soares H, Wager TT, Schmidt AW, et al. H3 receptor antagonism increases methylhistamine levels in the cerebrospinal fluid of dogs and healthy human volunteers. Alzheimers Demen 2009;5:P254-5
86. Available from: http://clinicaltrials.gov; Identifier: NCT00730990 A phase I, healthy volunteer positron emission tomography study. [Last accessed 15 June 2011]
87. Available from: http://clinicaltrials.gov; Identifier: NCT01346163 Add on treatment for cognitive deficits in schizophrenia. [Last accessed 15 June 2011]
88. Available from: http://clinicaltrials.gov; Identifier: NCT00531752 A study to evaluate the efficacy and safety of two doses of PF-03654746 in adults with attention deficit hyperactivity disorder (ADHD). [Last accessed 15 June 2011]
89. Available from: http://www.pfizer.com/files/research/pipeline/2009-0331/ pipeline-2009-0331.pdf [Last accessed 22 May 2011]
90. Available from: http://clinicaltrials.gov; Identifier: NCT01028911 A study to evaluate the safety, tolerability, and blood levels of PF-03654746 in subjects with mild to moderate Alzheimer's disease. [Last accessed 15 June 2011]
91. Available from: http://www.pfizer.com/files/research/pipeline/2010-0927/ pipeline-2010-0927.pdf [Last accessed 22 May 2011]
92. Available from: http://www.pfizer.com/files/research/pipeline/2011-0228/ pipeline-2011-0228.pdf [Last accessed 22 May 2011]
93. Available from: http://clinicaltrials.gov; Identifier: NCT01006122 A study of a novel compound for excessive daytime sleepiness associated with narcolepsy. [Last accessed 15 June 2011]
94. Available from: http://clinicaltrials.gov; Identifier: NCT00562120 A study to test a new decongestant in patients with allergic rhinitis following a nasal allergen challenge. [Last accessed 15 June 2011]
95. Romero FA Jr, Allan RJ, Phillips PG, et al. The effects of an H3 receptor antagonist in a nasal allergen challenge model. J Allery Clin Immunol 2010;125:AB191
96. Available from: http://www.ama-assn.org/resources/doc/usan/bavisant.pdf [Last accessed 24 August 2011]
97. Available from: http://clinicaltrials.gov; Identifier: NCT00915746 A drug interaction study of JNJ-31001074 and ketoconazole in healthy volunteers. [Last accessed 15 June 2011]
98. Available from: http://clinicaltrials.gov; Identifier: NCT01159821 A drug interaction study of 31001074 and paroxetine in healthy volunteers. [Last accessed 15 June 2011]
99. Available from: http://clinicaltrials.gov; Identifier: NCT00915668 A study to evaluate the pharmacokinetic drug interaction between multiple doses of JNJ-31001074 and a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel in women. [Last accessed 15 June 2011]
100. Available from: http://clinicaltrials.gov; Identifier: NCT00915434 A study to characterize the pharmacokinetics and effect of food on JNJ-31001074 in healthy volunteers. [Last accessed 15 June 2011]
101. Available from: http://clinicaltrials.gov; Identifier: NCT00890240 A study to evaluate pharmacokinetics, safety and tolerability after a single dose administration of of JNJ-31001074 in children (6-11 years) with attention deficit hyperactivity disorder (ADHD). [Last accessed 15 June 2011]
102. Available from: http://clinicaltrials.gov; Identifier: NCT00890292 A study to evaluate pharmacokinetics, safety and tolerability after a single dose administration of JNJ-31001074 in pediatric patients (12-17 years) with attention deficit hyperactivity disorder (ADHD). [Last accessed 15 June 2011]
103. Available from: http://clinicaltrials.gov; Identifier: NCT00566449 A safety and effectiveness study of JNJ-31001074 in adults with attention-deficit/hyperactivity disorder. [Last accessed 15 June 2011]
104. Available from: http://clinicaltrials.gov; Identifier: NCT00880217 A study to evaluate 3 different doses of JNJ-31001074 in the treatment of adults with attention-deficit/hyperactivity disorder (ADHD). [Last accessed 15 June 2011]
105. Available from: http://clinicaltrials.gov; Identifier: NCT01362699 Study of the efficacy of JNJ 31001074 on cue induced craving for alcohol. [Last accessed 15 June 2011]
106. Cowart MD, Esbenshade AT, Browman KE, et al. Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3-receptor antagonist. Inflamm Res 2010;59(Suppl 4):S305-59
107. Available from: http://clinicaltrials.gov; Identifier: NCT00888693 A multiple dose study of safety, tolerability, pharmacokinetics, and pharmacodynamics of ABT-288 in stable subjects with schizophrenia. [Last accessed 15 June 2011]
108. Available from: http://clinicaltrials.gov; Identifier: NCT01077700 Efficacy and safety study for cognitive deficits in adult subjects with schizophrenia. [Last accessed 15 June 2011]
109. Available from: http://clinicaltrials.gov; Identifier: NCT01018875 Efficacy and safety study of ABT-288 in subjects with mild-to-moderate Alzheimer's disease. [Last accessed 15 June 2011]
110. Available from: http://download.gskclinicalstudyregister.com/files/ 54aec5ef-45f3-492c-9e2d-ee823ef493af [Last accessed 22 May 2011]
111. Available from: http://clinicaltrials.gov; Identifier: NCT00474513 An imaging study to investigate the distribution of GSK239512 in the brain. [Last accessed 15 June 2011]
112. Available from: http://clinicaltrials.gov; Identifier: NCT00675090 Bridging study with GSK239512 in patients with mild to moderate Alzheimer's disease. [Last accessed 15 June 2011]
113. Available from: http://clinicaltrials.gov; Identifier: NCT01009255 Study to evaluate the efficacy and safety of GSK239512 in Alzheimer's disease. [Last accessed 15 June 2011]
114. Available from: http://clinicaltrials.gov; Identifier: NCT01009060 Study to evaluate the efficacy and safety of GSK239512 in schizophrenia. [Last accessed 15 June 2011]
115. Guillot E, Pichat P, Griebel G, et al. SAR110894, a novel, potent and selective H3-receptor (H3-R) a ntagonists: I. binding and functional characterization. 160.21/FF6. 2008 Neuroscience Meeting Planner. Society for Neuroscience; Washington, DC; 2008
116. Pichat P, Boulay D, Terranova J-P, et al. SAR110894, a novel, potent and selective H3-receptor (H3-R) antagonists: II. effects in models predictive for therapeutic activity against cognitive and addention deficits in schizophrenia and ADHD. 160.20/FF5. 2008 Neuroscience Meeting Planner. Society for Neuroscience; Washington, DC; 2008
117. Black M, Pichat P,Weiner I, et al. SAR110894, a novel, potent and selective H3-receptor (H3-R) antagonists: III. Potential activity in positive symptom and cognitive domains of schizophrenia using latent inhibition (LI) models in the rat. 160.19/FF4. 2008 Neuroscience Meeting Planner. Society for Neuroscience; Washington, DC; 2008
118. Available from: http://en. sanofi.com/binaries/070917-PDF-Slides-media-1- tcm28-15741.pdf [Last accessed 15 June 2011]
119. Available from: http://clinicaltrials.gov; Identifier: NCT01266525 Effect of different doses of SAR110894D on cognition in patients with mild to moderate Alzheimer's disease on Donepezil. [Last accessed 15 June 2011]
120. Schneider JS, Decamp E, Hill M, et al. Effects of the novel histamine H3 receptor antagonist S 38093 in a non-human primate model of cognitive dysfunction [abstract P4-342]. 12th International Conference Alzheimer's related diseases. Vienna; 2009
121. Available from: http://public.ukcrn.org.uk/Search/StudyDetail.aspx? StudyID=5282 [Last accessed 22 May 2011]
122. Available from: http://oss-sper-clin. agenziafarmaco.it/cgi-bin/ossc- view-pub? CODICE-PROT=CL2-38093-009& TITOLO-PROT=& FILE=scheda-part- pub& AZIONEFORM=VIEW& ID-SPER=46877& [Last accessed 22 May 2011]
123. Available from: http://www.taylorwessing.com/uploads/tx- siruplawyermanagement/scrip-rehmann-morgan.pdf [Last accessed 22 May 2011]
124. Available from: http://clinicaltrials.gov; Identifier: NCT00673465 Effect of SCH 497079 on metabolic parameters and influence of race/ethnic origin on therapeutic response (study P05338AM1) (completed). [Last accessed 15 June 2011]
125. Available from: http://clinicaltrials.gov; Identifier: NCT00642993 Efficacy and safety trial to evaluate the effect of SCH 497079 on weight in obese and overweight subjects (study P05483)(completed). [Last accessed 15 June 2011]
126. Chemical & Engineering News, 89(16) page 37, April 18, 2011
127. Hudkins RL, Raddatz R, Tao M, et al. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, Irdabisant): a potent, selective histamine H3 receptor inverse agonist. J Med Chem 2011;published online 2 June 2011; doi: 101021/jm200401v 2011 Jun 2.
128. Hudkins RL, Raddatz R, Tao M, et al. Discovery and characterization of CEP-26401: A potent, selective histamine H3 receptor inverse agonist. 241st ACS National Meeting & Exposition; 27-31 March 2011; Anaheim, California
129. Available from: http://phx.corporate-ir.net/External.File?item= UGFyZW50SUQ9Mzc1MTkwfE NoaWxkSUQ9MzczNTM5fFR5c GU9MQ==&t=1 [Last accessed 24 August 2011]
130. Hudkins RL, Aimone LD, Bailey TR, et al. Identification of pyridazin-3-one derivatives as potent, selective histamine H(3) receptor inverse agonists with robust wake activity. Bioorg Med Chem Lett published online 30 June 2011; doi: 101016/jbmcl201106108 2011 Jun 30
131. Grottick AJ, Barrera G, Edwards J, et al. Characterization of APD916, a novel histamine H3 antagonist with wake promoting properties. 285.4/QQ20. 2008 Neuroscience Meeting Planner. Society for Neuroscience; Washingtion, DC; 2008
132. Available from: http://files.shareholder.com/downloads/ARNA/ 1233974285x0x410899/ede6e0ff-a34e-4372-8fbf-1c8b00d6e161/ARNA-News-2010-10-20- General.pdf [Last accessed 22 May 2011]
133. Available from: http://www.astr azeneca.com/cs/Satellite? blobcol=urldata&blobheader=application%2Fpdf&blobheadername1= Content-Disposition&blobheadername2= MDT-Type&blobheadervalue1= inline%3B+filename%3D Download-pipeline-summary.pdf&blobheadervalue2= abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs& blobwhere=1285619440126 &ssbinary=true [Last accessed 22 May 2011]
134. Available from: http://clinicaltrials.gov; Identifier: NCT01121302 Study to investigate single ascending oral doses of AZD5213 in healthy male and non fertile female subjects. [Last accessed 15 June 2011]
135. Available from: http://clinicaltrials.gov; Identifier: NCT01171105 Study to investigate multiple ascending oral doses of AZD5213 in healthy male and non fertile female subjects. [Last accessed 15 June 2011]
136. Available from: http://clinicaltrials.gov; Identifier: NCT01335451 Assess the safety, tolerability and pharmacokinetics of AZD5213 after single and multiple ascending oral doses in healthy young and elderly Japanese subjects. [Last accessed 15 June 2011]
137. Available from: http://clinicaltrials.gov; Identifier: NCT01194986 Evaluation of histamine H3 receptor radioligand [11C] AZ12807110 and histamine H3 receptor occupancy of AZD5213 after oral administration. [Last accessed 15 June 2011]
138. Available from: http://www.ttpharma.com/TherapeuticAreas/ MetabolicDiseases/Obesity/HPP404/tabid/128/Default.aspx [Last accessed 22 May 2011]
139. Aslanian R, Mutahi M, Shih NY, et al. Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine. Bioorg Med Chem Lett 2003;13(12):1959-61 (Pubitemid 36638389)
140. Norman P. New H1/H3 antagonists for treating allergic rhinitis: WO2010094643. Expert Opin Ther Patent 2011;21(3):425-9
141. Procopiou PA, Browning C, Buckley JM, et al. The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis. J Med Chem 2011;54(7):2183-95
142. Clark K, Russell L, Hall D, et al. Preclinical pharmacology of the novel intranasal dual histamine H1 and H3 receptor antagonist GSK1004723. Allergy 2009;64(S90):129
143. Slack RJ, Russell LJ, Hall DA, et al. Pharmacological characterisation of GSK1004723, a novel, long acting antagonist at histamine H1 and H3 receptors. Br J Pharmacol 2011; published online 24 February 2011; doi: 101111/j1476-5381201101285x 2011
144. Available from: https://pharmainpartnership.gsk.com/Account/Datasheet. aspx/44350182 [Last accessed 22 May 2011]
145. Ford A, Browning C, Russell L, et al. Preclinical pharmacology of the novel oral dual histamine H1 and H3 receptor antagonist GSK835726. Allergy 2009;64(S90):69
146. Black LA, Nersesian DL, Sharma P, et al. 4-[6-(2-Aminoethyl)naphthalen-2- yl] benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration. Bioorg Med Chem Lett 2007;17(5):1443-6
147. Procopiou PA, Ancliff RA, Bamford MJ, et al. 4-acyl-1-(4- aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brainpenetrant histamine H3 receptor antagonists. J Med Chem 2007;50(26):6706-17 (Pubitemid 350309108)